AcquisitionsAug 6, 2026, 07:09 AM
Tarsus Pharmaceuticals to Acquire Alkeus; Q2 XDEMVY Sales Up 69% to $173.9M
AI Summary
Tarsus Pharmaceuticals announced strong second quarter 2026 financial results, with XDEMVY net product sales reaching $173.9 million, a 69% increase year-over-year. The company also raised its full-year 2026 XDEMVY sales guidance to $685-705 million. Additionally, Tarsus announced a pending acquisition of Alkeus Pharmaceuticals, which will expand its retina pipeline with a Phase 3 clinical program for Stargardt disease, supported by a $125 million private placement financing.
Key Highlights
- Pending acquisition of Alkeus Pharmaceuticals to expand retina pipeline with a Phase 3 program.
- Alkeus acquisition includes ALK-001 for Stargardt disease, affecting over 36,000 US patients.
- Priced $125 million private placement financing for the Alkeus acquisition.
- Q2 2026 XDEMVY net product sales were $173.9 million, a 69% increase year-over-year.
- Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million.
- Reported a Q2 2026 net loss of $18.6 million, an improvement from $20.3 million loss in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $449.7 million as of June 30, 2026.
- TP-04 Phase 2 KORE trial for ocular rosacea topline data expected in H1 2027.
Price Impact
More from TARS